Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)

SAN BRUNO, Calif. and LOS ANGELES, April 26, 2018 -- (Healthcare Sales &Marketing Network) -- Neuraltus Pharmaceuticals, Inc., a privately-held pharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases, today a... Biopharmaceuticals, Neurology Neuraltus Pharmaceuticals, Amyotrophic Lateral Sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
We describe a 19-year-old woman who was admitted to our hospital because of rapidly progressive dysarthria and dysphagia, developing over the course of 3  months. She had no family history of neurological diseases including essential tremor and no consanguineous history. Her delivery was non-eventful. In elementary school, her school records were not so bad, but she was not able to get along with her classmates.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
New research, led by Harvard scientists, identifies a novel potential therapeutic target for treating amyotrophic lateral sclerosis (ALS).
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Muscular Dystrophy / ALS Source Type: news
.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
.
Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration - Category: Neurology Authors: Source Type: research
ConclusionWhen caring for patients with ALS, the perioperative team must be prepared to treat potentially complex medical conditions that may not be directly related to the procedure and anesthetic management. However, minor procedures performed with minimal sedation may be safely performed on an ambulatory basis.
Source: Journal of Anesthesia - Category: Anesthesiology Source Type: research
Series Type : Expression profiling by high throughput sequencingOrganism : Mus musculusMutations in coding and non-coding regions of FUS cause amyotrophic lateral sclerosis (ALS). The latter mutations may exert toxicity by increasing FUS accumulation. We showhere that broad expression within the nervous system of wild type or either of two ALS-linkedmutants of human FUS produces progressive motor phenotypes accompanied bycharacteristic ALS-like pathology. FUS levels are autoregulated by a mechanism in whichwild type or ALS-linked mutants of human FUS downregulating endogenous FUS at bothmRNA and protein levels. Increasing ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
More News: ALS | Brain | Marketing | Neurology | Pharmaceuticals | Study